Company Profile - WAVE Life Sciences Ltd.

Introduction

Wave Life Sciences Ltd (Wave Life Sciences) discovers, develops, and commercializes medicines for genetic diseases. The company's pipeline consists of an mRNA transcript candidate: WVE-120101 and WVE-120102 for Huntington's disease; ATXN3 gene candidate for Spinocerebellar ataxia 3; C9orf72 gene candidate for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD); USH2A and RhoP23H candidate for retinal diseases; and multiple candidates for other central nervous system (CNS) disorders, and hepatic diseases. The company employs its proprietary chemistry platform to design, optimize and manufacture stereopure oligonucleotides with improved safety, tolerability and efficacy compared to that of stereorandom oligonucleotides. Wave Life Sciences is jointly advancing its CNS pipeline candidates in collaboration with Takeda. It has operations in Singapore, the US, Japan, the UK, and Ireland. Wave Life Sciences is headquartered in Singapore city, Singapore.